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Meta-Analysis of Quality of Life Constructs in
Antihypertansive Drug Theraphies

Abstract: Objectives : It is usually accepted
that some of the treatments affect not only
the survival times but as well the quality of
life of patients. The aim of study is to reach
more reliable conclusions by using the metaanalysis method on published studies which
deal with the effects of antihypertansive
theraphies on the quality of life of patients.
Material and Methods : Meta-analysis is
used to combine the results of different
experiments or studies examining the same
question. Meta-analysis is a systematic
reviewing strategy for adressing research
question that is especially useful when results
from several studies disagree with regard to
magnitude or direction of the effect, when
sample sizes are small to detect an effect and
label it statistically significant, or when a
large trial is too costly and time consuming to
perform. The effect size, d, is the difference
between the means in standard score form ,i.e.,
the ratio of the difference between the
means to the standard deviation.
Results : When quality of life is considered
meta-analysis results showed, except sexual
function, positive effect sizes for sleep,
general well-being and psychomotor scores
(ave(d)=-0.03; ave (d)=0.11; ave (d)=0.135;
ave (d)=0.40 Standard Deviations, respectively
). When the effect of drug grups on the

Introduction
It is usually accepted that some of the treatments
effect not only the survival times, but as well, the quality
of life of patients. For this reason , in the selection of the
treatment, its effects on the quality of life of patients
should also be taken into account (1). As an example
hypertension, is a kind of disease which is sometimes
asymptomatic or shows mild symptoms which does not
have adverse effects on the life of patients. By means of
antihypertansive treatments, the aim is not only to
remove the symptoms but to avoid some possible complications that may occur in future as well. Since such treatments last too long, it is noted that nearly 50% of the
patients drop out the treatment and only 30% of the
patients obey the rules of the treatment with recom-

recovery of patients are studied ave (d) is
found to be 0.17 for ACEI (p>0.05) and
0.20 SD (p>0.05) for BETA. When the effect
of ACEI drug group on psychomotor scores
of patients is considered, Meta-analysis
results yielded a mean effect size of 0.50 SD
(p<0.01). The mean effect size was 0.40 SD
for BETA drug group (p<0.01). The effect
of BETA drug group on sexual function
scores was the smallest effect ( ave (d)=0.103 ; p>0.05 ).
Conclusions : Among all of the applied metaanalysis, none of the drug groups showed
negative effects. Meta-analysis results when
quality of life is considered showed, except
sexual function positive effect sizes for sleep,
general well-being and psychomotor scores
(ave (d)=-0.03; ave (d)=0.11; ave (d)=0.135;
ave (d)=0.40 Standard Deviation, respectively).
Different drug groups have different effect
sizes on the dimensions of quality of life of
patients. Therefore, as well as this study, all
other studies in this field meta-analysis which
use , will help researchers to choose the best
strategy on deciding the type of the drug.
Key Words: Meta-analysis, Antihypertansive
Drug Therapy , Hypertension , Quality of
life, Clinical Trials

mended dosage and duration, which leads to failure to
achieve success by means of the treatments. Some of the
researchers indicate that, this is majorly due to the
adverse effects of the treatment on the quality of life of
patients. Therefore in the assessment of the success of
many kinds of treatments, their role on the quality of life
of patients started to gain importance in recent years (1).
The studies which deal with this topic are neither too
much nor use adequate number of subjects, thus yielding
results which are not very reliable and may produce incorrect results. This may primarily due to the subjects included in the studies have different characteristics . Metaanalysis brings these small or medium sized researchs
together to produce more exact results and tries to
explore the effects of different characteristics of subject
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used in different studies on the quality of life of patients
(2).
The aim of this study is to reach more reliable conclusions by using the meta-analysis method on published
studies, which deal with the effects of antihypertansive
drug therapies on the quality of life of patients.
Materials and Methods
Meta – Analysis : Meta-analysis is used to combine
the results of different experiments or studies examining
the same question (2,3,4,5,6,7). Meta-analysis is a systematic reviewing strategy for addressing research questions, that is especially useful when results from several
studies disagree with regard to magnitude or direction of
effect, when sample sizes are small to detect an effect and
label it statistically significant, or when a large trial is too
costly and time consuming to perform (4,8,9,10).
It's important to state the objectives of the metaanalysis at the beginning. First the goals of the metaanalysis should be formulated. The second step is the literature search in which the relevant published studies are
gathered. Literature search can be made either by using
computers or manually. However some researchers are in
favor of manual research which will be conducted by a
professional librarian. Studies are chosen for meta-analysis on the basis of inclusion and exclusion criteria. In order
to reduce bias, the inclusion of studies should be based on
predetermined criteria. The inclusion criteria may deal
with study design, sample size, type of experimental and
control therapies and the outcome of interest. The forth
step is the data collection phase. It is probable that the
results of the same study may be published in different
articles with slight changes. The user, therefore, should
be very careful and should not handle these articles as different studies ( 2,3,8).
There are different types of meta-analysis . For significance levels (p-values), correlation coefficients, ODDS
ratios or relative risks and effect sizes (d-indicies) different meta-analysis methods are used (2).
d-Index : The effect size, d , is the difference between the
means in standard score, i.e., the ratio of the difference
between the means to the standard deviation which is the
pooled standard deviation used in analysis of variance.
Generally, d-index is used when independent or dependent groups would be compared (2,5,11).
Cohen’s classification for d-index is as following (11) ;
d = 0.20 SD Small Effect Size
d = 0.50 SD Medium Effect Size
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d = 0.80 SD Large Effect Size
In different study designs, different formulations of dindex are used.
The d-index, in case of two independent groups is computed by (2) ;
d = ( YE – YC ) / Sw
Where ;
YE = The mean of experimental group
YC = The mean of control group
Sw = The pooled standard deviation
In case of repeated measures design, the dindex (2) ;
d = [ Ave(Y2) – Ave(Y1) ] / SD
Where ;
Ave(Y2) : The mean of posttest values
Ave(Y1) : The mean of pretest values
SD :
SD(Y2)=SD(Y1)=SD

The standard deviation and

If

If SD(Y2)#SD(Y1) then the mean of the two standard deviation is taken as SD.
The significance of d-index is tested with t =[d/ (N)1/2 ]/2. The
calculated t value is compared with the tabulated t value
with (N-1) degrees of freedom and with α error probability ( N is the total sample size ) (2).
Bare-Bones Meta-Analysis : In this study Bare-bones
meta-analysis, developed by J.E.Hunter and F.L.Schmidt,
for the analysis of the effect sizes of group means (dindex) is used (2). This analysis allows a correction for
sampling errors.
The average d-index in this type of meta-analysis is ;
Ave(d) = ∑ Wi di / Wi
Where ;
Wi = The sample size of the i th study
di = The d-index of the i th study
The correspondingly weighted variance of d-index is;
Var(d) = ∑ Wi [ di – Ave(d) ]1/2 / ∑Wi
The average sampling error variance is ;
Var(e) = { (N-1) / (N-3)} { (4 / N) ( 1+Ave(d)2 / 8 ) }
Where ;
N = ∑ Wi / K
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Wi = The sample size of the i th study
K = The number of studies included in metaanalysis
Quality of Life Dimension :
I. Physical construct ( sleep , sexual function )

defined by dividing the average change between the pre
and post treatment values by the average of the standart
deviation.
As a result, psychomotor construct is found to be the
factor which has the greatest effect, according to Cohen’s
Table 2:

II. Intellectual construct ( Psychomotor )
III. Emotional ( General well-being )

The Distiributon of Studies by quality of life construct and
drug group *

Inclusion of Studies to Meta – Analysis

Grouping Factor

Study (K)

Total Sample Size

Source of Data : Data for inclusion in the meta-analysis
were identified through a medline search of literature
from 1985 to 1992 by using “ quality of life, clinical trials, hypertension, antihypertansive therapy “ as keywords. No Turkish study could be found in this search.

All Studies

7

1407

General-Well Being

4

822

Sleep

5

828

Inclusion and Exclusion Criteria : Randomized single or
double blind clinical trials which present the required
quality of life parameters and type of antihypertansive
drugs are included to the study (Table 1 and Table 2 ).

Psychomotor

6

1368

Sexual Function

4

822

ACEI

5

357

BETA

5

325

Table 1:

The Studies Included In Meta-Analysis

By Construct

By Drug Group

Study

Reference No

Drug Group *

Blumenthal et.al. 1988

12

BETA

Blumenthal et al.1990

13

BETA,ACEI

Croog et al. 1986

14

ACEI, BETA

effect size classification ( Ave(d)=0.40 SD ) (11). It was
also concluded that sexual function had no positive effect
and the baseline scores were better.

Croog et al. 1990

15

ACEI,BETA

Therapy Effect by Quality of life Construct :

Fletcher et al. 1990

16

ACEI,BETA

Goldstein et al.1990

17

BETA

Kales et al. 1988

18

BETA

When the d-values related to “ General-well being “
from different studies are tested for significance, it was
observed that none of them were statistically significant
(p>0.05). After meta-analysis, however, the average
effect size was found as 0.135 SD and this value is statistically significant (p<0.05). When sleep construct is
considered , neither the effect size of individual studies,
nor the average effect size (Ave(d)=0.11 SD) calculated
by meta-analysis, were found to be significant. In case of
psychomotor construct, one of the studies reported
a highly significant result (p<0.01), three studies reported significant results (p<0.05), and the rest failed to find
a significant difference. When meta-analysis is applied to
all of these studies, the average effect size was 0.40 SD,
which is a very significant result (p<0.01).

* BETA ; β-blocker
ACEI ; angiotensin converting enzyme inhibitor

Results
Table 2 displays the patient characteristics and study
design of 7 published articles in which 9 drugs among 2
pharmacological drug groups were used.
In this study physical (sexual function, sleep), intellectual (psychomotor) and emotional (general well-being)
dimention of quality of life are evaluated. Other dimension such as social construct ( life satisfaction, social participation and working performance ) is not included due
to the lack of sufficient data. For each study, effect size
in repeated measures (d-index) is calculated by using
Hunter and Schmidt bare-bones meta-analysis which is

* Studies which include the above constructs

When sex scores are examined, none of the individual
studies reported significant differences (p>0.05). These
results also agree with that of the meta-analysis result,
from which the average effect size was - 0.03 SD, which
is a very small negative value, indicating a nonsignificant
effect (p>0.05).
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Figure 1.

Treatment Effect Sizes by Quality
of Life Constructs
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Figure 2.

Treatment Effect Sizes By Drug
Groups

Figure 3.

Treatment Effect Sizes by Drug
Groups and Quality of Life
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Therapy Effect by Drug Groups :

Discussion

When the quality of life scores of patients before and
after the therapy were studied for ACEI and BETA
groups, average effect sizes were 0.17 SD ( p>0.05), and
0.20 SD (p>0.05) respectively. These are classified as
having small effect sizes (11).

Although the side effects of antihypertansive drugs
were clearly defined by many researchers , their effects in
quality of life was not so explicit (19). For this reason ,
the need for meta-analysis is obvious.

Therapy Effect by Quality of Life Construct and
Drug Groups :
When the effect of ACEI group drugs on the psychomotor scores of patients were evaluated in different
studies, it was observed that two studies yielded highly
significant results (p<0.01) and two studies nonsignificant results (p>0.05). However, when meta-analysis was
conducted on these studies, the results was also significant with an effect size of 0.50 SD and an average effect
according to Cohen’s classification. For the BETA group ,
only one study reported significant, other studies reported nonsignificant results.Meta-analysis on this drug
groups showed significant effect ( Ave(d)=0.40 SD ).
Both the individual studies and meta-analysis revealed
that the BETA type drugs produced the smallest effect on
sexual function scores (Ave(d)= - 0.103 ;p>0.05), and
this led us to conclude that the sexual function scores of
patients were higher (better) before the treatment.

Beto and Bansal (19) used the meta-analysis techniques derived by Hedges and Olkin .
In this study , Hunter and Schmidt’s meta-analitic
methods were used and the results were compared with
the above mentioned method .
Our results agreed with Beto and Bansal’s, in the sense
that, both concluded psychomotor construct had the
highest effect . However , the effect size found in this
study was slightly higher ( 0.43 SD v.s. 0.283 SD ). Non
significant effect sizes for two drug groups also agree
with Beto and Bansal‘s findings .
In both studies , when both drug groups evaluated
together only sexual function construct had a negative
effect size . The same was also observed in BETA drug
group.
We expect , these meta-analysis results will be helpful to the researchers in their future antihypertansive clinical studies.
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